Secretory human carbonic anhydrase VI (CA VI) has emerged as a potential drug target due to its role in pathological states, such as excess acidity-caused dental caries and injuries of gastric epithelium. Currently, there are no available CA VI-selective inhibitors or crystallographic structures of inhibitors bound to CA VI. The present study focuses on the site-directed CA II mutant mimicking the active site of CA VI for inhibitor screening. The interactions between CA VI-mimic and a series of benzenesulfonamides were evaluated by fluorescent thermal shift assay, stopped-flow CO 2 hydration assay, isothermal titration calorimetry, and X-ray crystallography. Kinetic parameters showed that A65T, N67Q, F130Y, V134Q, L203T mutations did not influence catalytic properties of CA II, but inhibitor affinities resembled CA VI, exhibiting up to 0.16 nM intrinsic affinity for CA VI-mimic. Structurally, binding site of CA VI-mimic was found to be similar to CA VI. The ligand interactions with mutated side chains observed in three crystallographic structures allowed to rationalize observed variation of binding modes and experimental binding affinities to CA VI. This integrative set of kinetic, thermodynamic, and structural data revealed CA VI-mimic as a useful model to design CA VI-specific inhibitors which could be beneficial for novel therapeutic applications.
limitations, such as the largely unknown CO 2 concentration and unfeasibility to measure inhibition constant below several nM 26 . Therefore, biophysical techniques, such as the fluorescent thermal shift assay (FTSA) and isothermal titration calorimetry (ITC), are promising alternatives to screen CA-targeting derivatives. FTSA is a high-throughput method exhibiting minimized biomolecule consumption and low limitations for binding affinity, thereby both strong (picomolar) and weak (millimolar) compounds can be identified during the same experiment [26] [27] [28] [29] . ITC allows the direct determination of stoichiometry and thermodynamic parameters, such as affinity, enthalpy, entropy, and heat-capacity, during a single or several titration experiments but it demands relatively large quantities of proteins and has limitations for assessing the binding affinity 26, 30, 31 . Importantly, two types of variables can be distinguished when binding reactions are carried out by FTSA or ITC: the observed parameters obtained from experimental setup and the intrinsic values calculated according to the corresponding observed data. Most studies on the development of CA inhibitors usually provide only observed binding parameters, which are dependent on experimental conditions and might be misleading. Both the CA and inhibitor exist in different protonation states in the solution compared with ones in the complex. Therefore, protonation-deprotonation reactions are required to initiate the binding of inhibitor to CA. Only intrinsic values subtract energetic contribution of binding-linked protonation events and thus are relevant for the rational drug design [32] [33] [34] [35] . Due to the recent advances in the structural and in silico biology, production of target recombinant proteins, including CAs, in large quantities is of high demand for in vitro inhibitor screening of drug-candidates during preclinical research. The literature lists a number of host cells for expression of recombinant proteins. Among microorganisms, the enterobacterium Escherichia coli (E. coli) is selected frequently owing to numerous advantages, such as rapid growth, easy genetic manipulation, and relative cost effectiveness 36, 37 . However, the stability of heterologous protein in E. coli can be influenced by the several factors, including mRNA instability, codon bias, protein aggregation, toxicity, and lack of post-translational modification 38, 39 . Therefore, different, more efficient strategies to obtain functionally active recombinant proteins in high yield are required for screens of chemical compounds with the aim to identify hits in the initial stages of drug discovery.
The goal of the present study was to design a CA II-based CA VI model protein, named as CA VI-mimic, for the search of CA-isoform selective inhibitors. As CA VI-mimic, mutant of CA II containing five point mutations, such as A65T, N67Q, F130Y, V134Q, L203T, was generated via site-directed mutagenesis. CA II was selected as a core for CA VI-mimic because purification yield of CA II from E. coli is ~10-fold higher than CA VI, CA II has highest catalytic efficiency among CAs, and CA II is confirmed as a stable CA protein for X-ray crystallography. Here enzymatic activity and inhibition of CA II, CAVI-mimic, and CA VI was determined by SFA. Biophysical studies on inhibitor binding to CA II, CA VI-mimic, and CA VI were carried out by ITC and FTSA. X-ray crystallography and computational modeling were used to compare positions of several inhibitors in the active sites of CA II, CA VI-mimic, and CA VI. Observed and intrinsic thermodynamics were in line with structural results which confirmed the relevance of CA VI-mimic as a CA VI model protein. The most tested benzenesulfonamides bound to CA VI-mimic in a manner corresponding to their interactions with CA VI but not CA II, thereby emphasizing suitability of the investigated CA II mutant mimicking CA VI for inhibitor screening.
Results
Enzymatic activity of CA VI-mimic correlates with CA II, but not CA VI. Studies on inhibitor selectivity towards diverse human CA isoforms are important to develop efficient compounds for the treatment of diseases caused by abnormal levels or activities of a particular CA isoform. Therefore, it is essential to evaluate inhibitor affinity to all human CAs, including CA VI. Since our previous study 40 indicated a low yield of recombinant CA VI from E. coli, we generated CA II mutant as a CA VI model protein (CA VI-mimic) for inhibitor screening. Inhibitor affinities towards CA II and CA VI-mimic were expected to differ in the way imitating inhibitor binding to CA VI, but not CA II (Fig. 1A) . Thus, negligible differences between inhibitor affinities towards CA VI and CA VI-mimic were presumed. According to computational modeling, five point mutations A65T, N67Q, F130Y, V134Q, L203T were chosen (Figs 1B-D and S1) and introduced into the active site of CA II.
The catalytic activity of CA VI and CA VI-mimic to catalyze CO 2 hydration reaction was measured by SFA (Figs 2A and S3) . Analysis of kinetic data showed that site-directed mutagenesis did not significantly affect either the catalytic activity or pK a of zinc-bound water molecule of CA II. Catalytic constants (k cat ) of CA II and CA VI-mimic did not differ (k cat values were 6.0 × 10 5 s −1 ), whereas k cat for CA VI was lower than CA VI-mimic by 3-fold (1.9 × 10 5 s
−1
). In the pH range 5.9-7.0 Michaelis constants (K M ) as well as k cat values of the carbon dioxide hydration reaction were comparable: 7.3 ± 2.9 mM for CA II, 8.8 ± 1.8 mM for CA VI-mimic and 9.9 ± 3.2 mM for CA VI. However, in the pH range 7.1-8.4 K M values of CA VI-mimic (6.8 ± 2.0 mM) were closer to CA II (4.7 ± 1.0 mM) than to CA VI (11.3 ± 0.7 mM). Interestingly, maximum catalytic activity of CA VI was observed at pH 7.0-8.0 and it decreased at pH above 8.0. The determined pK a value of zinc-bound water molecule of CA VI was 6.6 ± 0.2. The observed inhibition constants by SFA correlated with dissociation constants determined by FTSA. Typical SFA curves of CA II, CA VI-mimic and CA VI inhibition by compound 39 are shown in Fig. 2B .
Influence of buffer and pH for the observed binding affinity of ethoxzolamide to CA VI-mimic.
Biophysical methods, such as ITC and FTSA, enable measurements of observed thermodynamics and thereafter calculations of intrinsic affinities. The observed binding profiles are altered by linked reactions and therefore, only intrinsic binding parameters can be correlated with compound structures, thereby revealing structural reasons for protein-ligand binding affinity.
Binding energetics are significantly affected by several protonation-deprotonation events which are necessary for the binding of sulfonamide derivative to CA. Only deprotonated sulfonamides can interact with the zinc cation in the active site of pronated CA, containing zinc-coordinated water molecule (protonated hydroxy group). In this study, observed and intrinsic affinities of inhibitor binding to CA VI-mimic were determined and compared to their affinities towards CA II and CA VI. The obtained experimental data by FTSA on interactions between ethoxzolamide (EZA) and CA VI-mimic in buffers with different pH showed that pH remarkably influenced the observed binding Gibbs energy (Δ b G obs , Fig. 3A ). The dependence of Δ b G obs on pH has also been observed previously 40, 41 when EZA binding to CA II or CA VI was measured. The strongest interaction was determined near neutral pH and became weaker both in acidic and alkaline pH. Sulfonamide group usually has pK a in the range between 7 and 10, whereas CA isoforms have pK a around 7. Therefore, diminished EZA affinity in acidic solution was because the fraction of binding-ready deprotonated form of EZA decreased by 10-fold with every pH unit. Similarly, EZA affinity decreased in alkaline solution because the fraction of binding-ready CA with the , whereas pK a s of CA VI and CA VI-mimic significantly differed by 1.0 pH (25 °C). Thus, target five point mutations of CA II, which were introduced to design CA VI-mimic, did not affect amino acids surrounding zinc in active sites of CA II at the level causing significant difference of pK a s between CA II and CA VI-mimic. Moreover, Δ p H for CA VI-mimic was assessed to be −38.0 kJ/mol at 25 °C. The difference of Δ p H between CA VI and CA VI-mimic (6.0 kJ/mol) was 2-fold lower than difference of Δ p H between CA II and CA VI-mimic (12.0 kJ/mol). Therefore, experiments with one inhibitor EZA resulted in both pK a and Δ p H for CA VI-mimic, which are essential parameters to determine intrinsic energetics of any other inhibitor binding to CA VI-mimic.
Hydrophobic substituents and fluorine substituents significantly affected intrinsic inhibitor binding affinity for CA VI-mimic. Here www.nature.com/scientificreports www.nature.com/scientificreports/ of raw and integrated data of inhibitor binding to CA VI-mimic by FTSA and ITC at different pHs are indicated in Fig. 2C ,D, respectively).
According to observed thermodynamics, EZA was shown to be the strongest binder to CA VI-mimic with observed www.nature.com/scientificreports www.nature.com/scientificreports/ K d_obs for 30 and 6 binding to CA VI-mimic increased 8-fold upon fluorination (from 1000 nM to 130 nM), whereas K d_obs for 23 and 22 increased affinity 10-fold (from 500 nM to 50 nM). Fluorines reduced pK a of sulfonamide group significantly: from 9.96 to 8.14 for inhibitors 30 and 6, respectively, and from 10.2 to 8.15 for compounds 23 and 22, respectively (Table 2) . Correspondingly, chlorine in most compounds also increased observed affinity and reduced pK a of inhibitor sulfonamide amino group. For example, upon chlorination K d_obs for 40 and 41 interaction with CA VI-mimic increased 430-fold (from 3600 nM to 8.3 nM, respectively), while pK a values were lowered by 1.30 unit (from 9.60 to 8.30, respectively).
To investigate structure-activity relationships, intrinsic K d (K d_intr ) values for interactions between CA VI-mimic and investigated series of compounds were calculated. The largest differences between K d_obs and K d_intr values were determined for nonfluorinated benzenesulfonamides (16, 23, and 30), where the binding to CA VI-mimic differed 2500, 3200, and 1800-fold, respectively. Only five compounds (10, 18, 26, TFS, and MZM) exhibited lower than 10-fold difference between the K d_obs and K d_intr . According to intrinsic thermodynamics, the strongest binders were inhibitors 16, 23, 30, and 33 with K d_intr in the range of 0.16-0.55 nM. Therefore, the strongest intrinsic interaction between inhibitor and CA VI-mimic was observed when inhibitor did not possess any fluorines in benzenesulfonamide scaffold and contained a hydrophobic substituent at para position, such as SCH2CH2CH3 (K d_intr for inhibitor 23 was 0.16 nM) and SCH2CH2Ph (K d_intr for inhibitor 16 was 0.20 nM). Exceptionally, inhibitor 33 was the strongest binder to CA VI-mimic with chlorine at ortho position and large hydrophilic group at meta position (K d_intr was 0.31 nM). Replacement of the methyl group (inhibitor 23) by hydrophilic hydroxyl group (inhibitor 30) weakened intrinsic binding affinity more than 3-fold (from to 0.16 nM to 0.55 nM). Moving on to the structural analysis of fluorinated benzenesulfonamides, two inhibitors were determined to be the strongest binders to CA VI-mimic: compound 5 bearing 4-Morpholinyl group at para position (K d_intr was 1.2 nM) and 22 with SCH2CH2CH3 group at para position (K d_intr was 1.7 nM). In line with results obtained from nonfluorinated compounds, hydrophobic contacts between inhibitors and CA VI were identified to be significant because the exchange of methyl group (inhibitor 22) by hydroxyl group (inhibitor 6) or carboxyl group (inhibitor 19) weakened intrinsic interaction by 2 and 9-fold, respectively. Apparently, the number of methyl groups of substituents at para position had significant effect on intrinsic binding affinity. The inhibitor 32 with SCH2Ph bound to CA VI-mimic 2-fold stronger than inhibitor 15 with SCH2CH2Ph and 4-fold stronger than inhibitor 9 with SPh. Most often, introducing diverse substituents at meta position did not change intrinsic binding affinity significantly (6 vs 25, 26 vs 28, and 26 vs 29), except for 26 vs 31 bearing large hydrophobic group which weakened interaction 9-fold. The compound 17 bearing two large and highly hydrophobic substituents at ortho and para positions was the weakest binder not only according to the observed parameters (K d_obs was 100 µM), but also intrinsic data (K d_intr of 1000 nM).
Thermodynamically CA VI-mimic binds benzenesulfonamides similarly to CA VI but differing from CA II. To evaluate if CA VI-mimic based on CA II is a suitable CA VI model protein for inhibitor screening, observed and intrinsic affinities represented by logarithmic K d values of inhibitor binding to CA II, CA VI-mimic, and CA VI were compared by applying linear regression. A higher linear correlation was determined between observed affinities of inhibitor binding to CA VI and CA VI-mimic (R 2 = 0.79) compared to the observed affinities of inhibitor interaction with CA II and CA VI (R 2 = 0.61; Fig. 5A ). Analysis of the calculated intrinsic parameters were in line with experimentally measured observed data, emphasizing a stronger correlation of the intrinsic thermodynamics of inhibitor binding to CA VI and CA VI-mimic (R 2 = 0.74) compared to that of CA II and CA VI-mimic (R 2 = 0.56; Fig. 5B ). Furthermore, regression line slopes indicating the comparison of inhibitor binding to CA VI and CA VI-mimic (0.74 for observed affinity, 0.95 for intrinsic affinity) were larger than the corresponding slopes for CA II and CA VI (0.54 for observed affinity, 0.58 for intrinsic affinity), 
The influence of investigated CA II mutations on inhibitor binding thermodynamics was further analyzed by calculating the absolute error (AE) values from logarithmic observed or intrinsic K d s of inhibitor binding to CA VI-mimic, CA II, and CA VI. According to the observed thermodynamics, binding affinities of only 12 inhibitors out of 46 tested compounds towards CA VI-mimic was more similar to CA II than CA VI. For the intrinsic data, only 6 compounds were identified as CA VI-mimic binders with the affinity more alike CA II compared to CA VI. Moreover, mean absolute errors (MAEs) as the averages for each AE were also evaluated. MAEs of AE obs,CA II and AE intr,CA II were equal to 1.1, while MAEs of AE obs,CA VI and AE intr,CA VI were significantly smaller, 0.47 and 0.41, respectively. Therefore, CA VI-mimic designed via site-directed mutagenesis from CA II was characterized to be a proper model of CA VI for observed and intrinsic inhibitor binding reactions.
Differences in inhibitor binding affinities are due different binding modes as determined by crystallographic analysis of CA II and CA VI-mimic. Despite numerous attempts, the crystal structures of recombinant CA VI complexes with sulfonamide-based inhibitors were not obtained by soaking. Even though CA VI crystals survived soaking procedure, crystals did not contain the clear electron densities of inhibitors. The co-crystallization of CA VI protein with several inhibitors failed, as we did not obtain any crystals suitable for X-ray diffraction experiment. Most likely, CA VI complexes with sulfonamide-based inhibitors cannot be crystallized using crystallization conditions that are effective for the unbound CA VI protein.
To structurally investigate the binding of benzenesulfonamides with CA VI, we have engineered CA VI-mimic and applied in crystallographic studies. We have solved crystal structures of CA VI-mimic complexes with three inhibitors (Fig. S2 ): EZA (PDB ID: 6QL2), inhibitor 14 (PDB ID: 6QL1), and 25 (PDB ID: 6QL3). These complexes were compared with the corresponding complexes composed of CA II and same ligands (EZA (PDB IDs: 3CAJ (X-ray), 6BCC (neutron diffraction)), inhibitor 14 (PDB ID: 4HT0), and 25 (4PYY)). The space groups and unit cell parameters of CA VI-mimic crystals were similar to those of CA II (Table 3 ). There was one unique protein-ligand complex in the asymmetric unit. CA VI-mimic binding pocket was found to be similar to CA VI according to crystallographic studies (Fig. 1D) followed by thermodynamic analysis. For this reason, the insights into the compound binding mode to CA VI-mimic are likely to be valid for analyzing the ligand binding data to CA VI.
The comparison of binding mode of inhibitor 14 in the active sites of CA VI-mimic and CA II is shown in Fig. 6A . Inhibitor 14 in the active site of CA VI-mimic had two alternative binding modes characterized by different positions of the fluorinated ring: the ring was either lodged between Leu198 and Thr200 side chains (colored cyan in Fig. 6A ), or located in the hydrophilic part of active site (colored blue). On the other hand, in the active site of CA II we had only one position of fluorinated ring -between Leu198 and Thr200. It looks like the replacement of Phe130 in CA II with tyrosine in CA VI-mimic enabled additional position of fluorinated ring of ligand due to a steric collision between the fluorine atom of fluorinated ring and the oxygen atom of Tyr130 side chain (the close contact found in the structure was 2.5 Å). The alternative position of the fluorinated ring of compound 14 in the active site of CA VI-mimic probably was available only due to spatial fluctuations of Tyr130 side chain. Also, due to a significantly larger size and the hydrophilicity of the side chain of Gln134 in CA VI-mimic compared to Val134 in CA II, the hydrophobic dimethylpyrimidine tail of inhibitor 14 was repelled in CA VI-mimic (see para-group of the cyan ligand, Fig. 6A) . Therefore, the change of size and the hydrophobicity/hydrophilicity of the residues 130 and 134 upon mutation could be rationalized as the main causes for the relatively significant difference in the binding affinities: inhibitor 14 bound to CA II 40-fold better than to CA VI-mimic (K d_intr values were 0.37 nM and 15 nM for CA II and CA VI-mimic, respectively; Table 2 ).
The model compound EZA was bound similarly in active sites of CA II and CA VI-mimic (Fig. 6B) . Some discrepancy was present only in the positions of highly flexible ethoxy moiety. The aliphatic-aromatic interactions between the methyl group of Leu198 and the first ring of EZA was present in both cases. The larger side chain of Tyr130 slightly changed the position of EZA aromatic ring in CA VI-mimic as compared with CA II due to steric conflicts. It is important also to note the role of the residue 134 interacting with the hydrophobic tail of EZA, similarly to the observation for inhibitor 14 above. The hydrophobic Val134 sidechain in CA II was mutated into hydrophilic Gln134 in CA VI, leading to the worsening of the interaction. Thus, the mutations of residues 130 and 134 were the likely reasons for 15-fold stronger binding of EZA to CA II, as determined by intrinsic thermodynamics (K d_intr values were 0.073 nM and 1.1 nM for CA II and CA VI-mimic, respectively; Table 2 ).
The intrinsic binding parameters of inhibitor 25 towards CA II and CA VI-mimic were comparable (2.2 nM vs 4.5 nM, respectively; Table 2 ). In contrast, the binding modes of the compound found in crystal structures were different in these active sites. In CA II, inhibitor 25 had two alternative conformations: (1) the fluorinated ring located between Leu198 and Thr200, whereas the cyclooctyl ring replaced the side chain of Phe130 (Fig. 6C , pink ligand); (2) the fluorinated ring positioned in the hydrophobic part of active site, while the cyclooctyl ring -in the hydrophilic part (Fig. 6D, pink ligand) . In CA VI-mimic, compound 25 had one well-defined conformation (Fig. 6C, D, blue) in which the cyclooctyl ring replaced the Tyr130 side chain, whereas the fluorinated ring occupied the hydrophilic part of active site. We can explain the presence of the single conformation of inhibitor 25 bound to CA VI-mimic. It seems that the mutation in position 67 (asparagine to glutamine) allows the position of fluorinated ring in hydrophilic part of active site when the para-substituent of ligand does not have sterical collision with side chain of residue 67 (compare side chain conformations of asparagine (CA II) and glutamine (CA VI-mimic), Fig. 6C, D) . The same position of glutamine is found in the complexes of CA VI-mimic with inhibitor 14 and EZA ligands which means that compound 25 does not influence the position of side chain of residue 67 in CA VI-mimic. The replacement of asparagine (CA II) to glutamine (CA VI-mimic) creates the additional free space in the active site and allows for another binding mode. 
Discussion
Nowadays enzymes encompass over one-third of drug targets investigated by large pharmaceutical companies 43 , thereby emphasizing the relevance of target-based drug approach. This strategy aims to identify the compounds which would exhibit the most therapeutically beneficial effect via modulating catalytic activity or expression levels of disease-associated enzymes. The present study is focused on CA VI isoform as a drug target due to the link of CA VI with several pathologies 19, 20, 22 . Even though several studies on the design of compounds targeting CA VI have been reported 40, 44, 45 , CA VI-selective inhibitor has not been discovered so far. Therefore, there is an interest in inhibitors with high affinity and selectivity against CA VI which would be crucial to reveal biological function of CA VI.
During preclinical development, numerous high-throughput screening assays are employed to design and optimize hits toward a target protein. Therefore, in vitro techniques require high quantities of recombinant proteins for the proper evaluation of compound quality, efficacy, and safety before testing in humans. Despite recent advances in molecular sciences, difficulties in the production of recombinant proteins in large scale are observed. Our previous study 40 indicated low yield of CA VI from E. coli. Here we have presented a strategy to apply CA VI-mimic as CA VI model protein for the investigation on enzymatic inhibition and inhibitor binding thermodynamics. The CA VI-mimic was designed via site-directed mutagenesis from CA II by introducing five point mutations, such as A65T, N67Q, F130Y, V134Q, and L203T. Such approach to obtain CA protein based on the CA II mutant for the search of CA-selective inhibitors has been successfully applied previously. It was due to troubles to obtain sufficient amounts of recombinant CA isoforms and enabled by high structural homology between human www.nature.com/scientificreports www.nature.com/scientificreports/ CAs. McKenna's group reported a number of structural studies on CA IX-mimic based on CA II mutant with 2 mutations (S65A, Q67N) 46-48 , 7 mutations (A65S, N67Q, E69T, I91L, F131V, K170E, L204A) 49-51 or 8 mutations (A9K, S65A, Q67N, T69E, L91I, V131F, E170K, A204L) 52 . Our group also published the exploration on inhibition parameters and binding thermodynamics via the application of CA IX-mimic as CA II mutant with 6 mutations (S65A, Q67N, L91I, V130F, L134V, A203L) and CA XII-mimic as CA II mutant with 6 mutations (S65A, K67N, T91I, A130F, S134V, N203L) 53 . The significant findings of the listed studies promoted the present investigation of CA II mutant mimicking CA VI. Over 10-fold higher purification yield of CA VI-mimic compared to CA VI from E. coli allowed kinetic, thermodynamic, and structural analyses of 43 benzenesulfonamides binding to CA VI-mimic. Even though the most tested inhibitors exhibited moderate affinities towards CA VI-mimic, this study provided insight into the structure-based design of inhibitors with better affinity and selectivity towards CA VI.
The observed kinetic parameters of CA VI and CA VI-mimic are consistent with previous works. The determined catalytic constant of CA VI compares reasonable well to published k cat value (3.4 × 10 5 s −1 ) 44 . The difference of k cat values most likely arise from the uncertain CO 2 concentration in the previous work. The CA VI-mimic had the same catalytic activity as CA II (k cat -6.0 × 10 5 s
) and confirmed previously published results that A65, N67, F130, V134, L203 amino acids in the active site of CA II are not important for catalytic activity [54] [55] [56] . Three 
The relevance of protonation-deprotonation reactions occurring additionally upon inhibitor binding to CA has been reviewed by several groups 57, 58 . Such protonation events have been recently confirmed by neutron crystallography 59, 60 . To generate compounds with great affinities by rational design, it is essential to understand the structural reasons for the changes in binding affinities of the investigated compounds towards the target. Only intrinsic parameters subtract the contribution of protonation reactions occurring in conjunction with the binding reaction between the CA and inhibitor. In the present study, nonfluorinated benzenesulfonamides exhibited stronger intrinsic and weaker observed binding affinity than corresponding fluorinated compounds. This result is in line with the previous investigation 34 , emphasizing the impact of fluorine electronegativity on the lowering of the pK a of inhibitor sulfonamide group but not the direct recognition of CA VI-mimic surface. The diminished pK a of fluorinated inhibitors led to the elevated observed affinity due to the increased fraction of inhibitor in the deprotonated form that bound to CA VI-mimic with the protonated zinc-bound hydroxide ion in the active site. Furthermore, substituents at ortho and para, but not meta positions were identified to be significant for the molecular recognition between the compound and CA VI. However, ortho and meta-substituted benzenesulfonamides have been recently shown to act as tight CA IX binders 32 . Therefore, such findings confirmed that intrinsic, but not observed parameters should be applied to analyze the dependence of binding efficiency on compound chemical structures, thereby allowing important structure-thermodynamics correlations to design CA-isoform selective inhibitors.
Inhibitor binding affinity can be significantly affected by structural properties of CA VI which have been widely investigated. The crystal structure of recombinant CA VI catalytic domain, lacking signal sequence and C-terminal region, has revealed its dimeric arrangement with the active sites of monomers facing each other and directed towards the center of the dimer 61 . Interestingly, the recent study 62 has indicated that pentraxin domain (PTX) is present in non-mammalian CA VI, whereas PTX-coding exon is not found in mammalian CA6 gene most likely due to rearrangements occurring upon the duplication of the adjacent glucose transporter genes. Instead of the PTX domain, mammalian CA VI contains a C-terminal region of at least 25 residues which is not detected in other vertebrate CA isoforms. This part of CA VI may be important to form oligomers and bind other proteins affecting CA VI enzymatic activity or causing biological effect as a consequence of CA VI-protein interactions. Therefore, in vitro and in vivo studies on targeting CA VI can yield discrepancies in results because of the structural differences between recombinant CA VI applied for inhibitor screening and endogenous CA VI of live model organisms, such as mice or zebrafish.
The combination of data obtained from enzymatic inhibition and biophysical binding methods, such as FTSA and ITC, significantly strengthens the conclusions of compound structure-activity relationships. Since techniques are based on different strategies to characterize inhibitor efficacies, the precision and accuracy of the measurements are necessary to reliably select the most potent and strongest inhibitors/binders. The uncertainty and repeatability of FTSA 42 and ITC 63, 64 measurements have been previously discussed. Furthermore, correlation between the affinities determined by FTSA and SFA or FTSA and ITC have been recently reported 26, 58 and confirmed in the present study. Therefore, both enzymatic inhibition and biophysical binding techniques are necessary for precise identification of inhibitors with great affinity and selectivity towards the particular CA isoform, thereby leading to the success in clinical development.
In conclusion, this study on site-directed mutagenesis of residues in the active site of CA II to resemble CA VI gave clues to the basis for isoform specificity of benzenesulfonamides towards CA VI over CA II. The characterization of numerous properties, such as kinetics of binding, inhibition profiles and the mechanism of action, provided the deeper insight into the efficacy of CA VI-targeting inhibitors. This in vitro step is crucial because only sufficiently characterized compound can result in the success on translating experimental data to a clinical disease setting. Moreover, the present kinetic, thermodynamic, and structural information is important for experiments in silico, such as machine learning, when current binding information will be determined, filtered, and extracted.
Methods
Synthesis of CA inhibitors. The synthesis of CA inhibitors has been previously described [65] [66] [67] [68] . EZA, MZM and TFS were purchased from Sigma-Aldrich (St. Louis, MO, USA) and were used without further purification. Figs 1D and 6(A-D) were performed using UCSF Chimera v. 1.12 69 . The residues within 5 Å from the typical CA II inhibitor in PDB entry 3M96 in both isoforms were analyzed, and five residues which were different between the isoforms were selected to create CA VI-mimic. The structure-based alignment was generated using PROMALS3D web server 70 . The sequence alignment figure was prepared using TeXshade package 71 . The expression vector pET15b-CA II 72 , encoding full length CA II (1-260), was used in site-directed mutagenesis. The residues located in CA II active site, A65, N67, F130, V134, and L203, were replaced to T, Q, Y, Q, and T, respectively. For each mutagenesis reaction two oligonucleotide primers (sense and antisense) with target mutation were used: A65T_s: 5'CTC AAC AAT GGT CAT ACT TTC AAC GTG GAG3' and A65T_a: CTC CAC GTT GAA AGT ATG ACC ATT GTT GAG; N67Q_s: CAA TGG TCA TAC TTT CCA GGT GGA GTT TGA TGA C and N67Q_a: GTC ATC AAA CTC CAC CTG GAA AGT ATG ACC ATT G; F130Y_s: CCA AAT ATG GGG ATT ATG GGA AAG CTG TGC AG and F130Y_a: CTG CAC AGC TTT CCC ATA ATC CCC ATA TTT GG; V134Q_s: GAT TAT GGG AAA GCT CAG CAG CAA CCT GAT GG and V134Q_a: CCA TCA GGT TGC TGC TGA GCT TTC CCA TAA TC; L203T_s: GAC CAC CCC TCC TCT TAC GGA ATG TGT GAC CTG and L203T_a: CAG GTC ACA CAT TCC GTA AGA GGA GGG GTG GTC. PCR was carried out with high fidelity Pfu DNA polymerase (Thermo Fisher Scientific), except V134Q created with Phusion DNA polymerase (Thermo Fisher Scientific). Composition of PCR: 1× polymerase buffer, 50 ng template DNA, 0.2 mM dNTPmix, 125 ng (2019) 9:12710 | https://doi.org/10.1038/s41598-019-49094-0 www.nature.com/scientificreports www.nature.com/scientificreports/ each sense and antisense primer, and 1.5 U DNA polymerase. Thermal cycling conditions: initial denaturation -95 °C for 10 min, then 18 cycles: 95 °C for 3 min, annealing -66 °C (A65T and F130Y), 63 °C (N67Q), 71 °C (V134Q), or 72 °C (L203T) for 2 min, extension -72 °C for 8 min, final extension -one time 72 °C for 10 min. After temperature cycling, PCR product was treated with Dpn I restriction endonuclease in order to digest the parental DNA template and to select new synthesized mutated DNA 73 . The mutations were confirmed by DNA sequencing.
Production of CA VI-mimic protein. The structural superpositions of proteins for
Expression of CA VI-mimic protein was carried out in E. coli BL21(DE3) strain. Transformed cells colony was transferred to LB medium, containing 100 µg/ml ampicillin, grown at 37 °C and 220 rpm for 16 h. Then the saturated culture was diluted (1:50) in fresh LB medium, containing 100 µg/ml ampicillin and 60 µM ZnSO 4 and grown to OD 600 ≈ 0.8. The expression of CA VI-mimic protein was induced with 0.2 mM isopropyl-β-D-thiogalactoside (IPTG) and 0.4 mM ZnSO 4 . The cells were grown over night at 19 °C, 220 rpm and harvested by centrifugation at 4000 g for 20 min at 4 °C.
The biomass was suspended in the lysis buffer (20 mM HEPES, 0.15 M NaCl, and 1 mM PMSF, pH 7.4), incubated at 4 °C for 60 min and then disrupted by sonication. Debris of cells and insoluble proteins precipitated after centrifugation at 30 000 g for 25 min. The soluble CA VI-mimic protein was purified using a metal chelate and CA-affinity chromatography. For the metal chelate chromatography the column was equilibrated with 20 mM HEPES, 0.15 M NaCl (pH 7.4). For elution of CA VI-mimic protein, solution composed of 20 mM HEPES, 0.15 M NaCl, and 0.2 M imidazole (pH 7.4) was used. Eluted protein was purified using a CA-affinity column containing p-aminomethylbenzene sulfonamide-agarose (Sigma-Life Science Aldrich). Sorbent was equilibrated with 20 mM HEPES, 0.15 M NaCl (pH 7.4). For the protein elution, solution composed of 0.1 M sodium acetate and 0.5 M sodium perchlorate (pH 5.6) was used. Eluted CA VI-mimic protein was dialyzed into storage buffer containing 20 mM HEPES, 0.05 M NaCl, pH 7.4, and stored at −80 °C.
The purity of CA VI-mimic protein was analyzed by SDS-PAGE. Protein concentrations were determined by UV-vis spectrophotometry using extinction coefficient ɛ 280 = 51910 M −1 cm −1 and confirmed by standard Bradford method. Molecular mass of CA VI-mimic protein was confirmed by Mass spectrometer: observed -29192.4 Da, theoretically predicted -29323.0 Da. The difference is due to Met residue removed during production.
Enzymatic activity and inhibition by SFA. Enzymatic activity and inhibition experiments were performed using an Applied Photophysics SX.18MV-R stopped-flow spectrophotometer at 23 °C. Saturated CO 2 solution was prepared by bubbling the CO 2 gas in Milli-Q water at 23 °C for 1 h. The concentration of CO 2 was determined using a model described previously 26 . Catalytic constants k cat and Michaelis constants K M of CA VI and CA VI-mimic were determined in a pH range from 6.0 to 8.4 using 25 mM buffer and 30-300 µM indicator systems with similar pK a values: MES (pK a 6.1) and Bromocresol Purple (pK a 6.4, λ -590 nm, pH 6.0-6.4), MOPS (pK a 7.2) and Bromothymol Blue (pK a 7.1, λ -615 nm, pH 6.8-7.1), HEPES (pK a 7.5) and Phenol Red (pK a 7.5, λ -557 nm, pH 7.2-7.8), TRIS (pK a 8.06) and m-Cresol Purple (pK a 8.3, λ -575 nm, pH 8.0-8.4). CA VI and CA VI -mimic concentration was 50-100 nM. The ionic strength of solution was maintained at 0.2 M by the addition of sodium sulfate. Maximal velocities v max were obtained using Lineweaver-Burk coordinates, and k cat , pK a values were determined using single ionization model: Enzyme inhibition experiments were performed using 25 mM HEPES buffer containing 0.2 M sodium sulfate and 50 µM Phenol Red indicator, pH 7.5. Enzyme concentration was 10-30 nM for CA II, and 50 nM for CA VI and 50-107 nM CA VI-mimic. Inhibitor concentration was 0-20 µM in <0.2% DMSO. Raw curves were fitted using a single exponential model and the inhibition constants were determined using Morrison equation 74, 75 : 50 2 where [CA] is the total concentration of the active CA molecules, [I] is the total added inhibitor concentration, and IC 50 is the concentration of inhibitor that achieves 50% inhibition of enzymatic activity. A dose-response curve was fitted using fixed CA concentration and assuming that it is equal to the active enzyme concentration.
Inhibitor binding by FTSA. FTSA measurements were performed using a Corbett Rotor-Gene 6000 (Qiagen Rotor-Gene Q) instrument using the blue channel (excitation 365 ± 20 nm, detection 460 ± 15 nm). Samples contained 10 µL of 10 µM CA VI-mimic protein, 10 µL of 0-200 µM inhibitor in 50 mM phosphate buffer at pH 7.0 containing 100 mM NaCl, 50 µM solvatochromic dye 8-anilino-1-naphthalene sulfonate (ANS) and a final DMSO concentration of 2%. The applied heating rate was 1 °C/min. The pH dependence of the observed binding constant was measured in universal buffer containing 50 mM sodium phosphate, 50 mM sodium acetate, 25 mM sodium borate at pH 5.0-10.0. Data were fitted and analyzed as previously described 72, 76 . Experiments were repeated at least twice.
Inhibitor binding by ITC. ITC measurements were performed using a VP-ITC instrument (Microcal Inc.,
Northampton, USA) with 1.4 mL of 4-6 µM CA VI-mimic protein solution in the cell and 300 µL of 40-60 µM ligand solution in the syringe. A typical experiment consisted of 25-30 injections (10 µL each) added at 200-240 s intervals. In order to determine the pH dependence of the observed binding enthalpy, experiments were performed at 25 °C in 50 mM phosphate or 50 mM TRIS buffer containing 100 mM NaCl at pH 5.0-10.0 with a final DMSO concentration of 1%, equal in the syringe and the cell. Data were integrated, fitted and analyzed as previously described 77 . Experiments were repeated at least twice. The fractions of binding-ready inhibitor and CA depend on the pK a of sulfonamide amino group (pK a_SA ) and the pK a of water molecule in the active site of CA (pK a_CA ), respectively. The intrinsic Gibbs energy change (Δ G b intr ) is associated with the change in K d_intr for the binding reaction.
